October 2, 2020
UCB Japan started to independently market and promote its antiepileptic agent E Keppra (levetiracetam) on October 1 as it wound up its collaboration with Otsuka Pharmaceutical after over 10 years. The two companies concluded a codevelopment and copromotion arrangement in...read more